News Updates
Innovative Regenerative Medicine Therapies – Patient Safety Comes First
Source: FDA
The U.S. Food and Drug Administration continues to facilitate the development and availability of innovative medical products, such as regenerative medicine therapies, that have the potential to treat or even cure diseases or conditions for which few effective treatment options exist.
Innovative Regenerative Medicine Therapies – Patient Safety Comes First
Source: FDA
The U.S. Food and Drug Administration continues to facilitate the development and availability of innovative medical products, such as regenerative medicine therapies, that have the potential to treat or even cure diseases or conditions for which few effective treatment options exist.
Regenerative medicine for neurological diseases—will regenerative neurosurgery deliver?
Source: thebmj
Regenerative medicine aspires to transform the future practice of medicine by providing curative, rather than palliative, treatments. Healing the central nervous system (CNS) remains among regenerative medicine’s most highly prized but formidable challenges.
Stem cell studies take time, but Arizona researchers say the wait is safer for patients
Source: azcentral
Researchers believe they're getting closer to getting approved stem cell treatments on the market, but it takes time.
Regenerative medicine: regulatory trends
Source: Pharmaceutical-Technology
The regulatory principles that apply for the clinical development of conventional therapies also apply to regenerative medicines.
Scientists identify small-molecule cocktail to improve stem cell use in research and disease treatments
Source: NIH
Researchers at the National Institutes of Health have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function.
Ortho regenerative technologies announces submission of investigational new drug application for Ortho-R
Source: PR Newswire
Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho RTI" or the "Company"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies
